Home › Trials › NCT05776225

Screening for pulmonary hypertension in patients with interstitial lung disease

Pulmonary Hypertension Screening in Patients with Interstitial Lung Disease for Earlier Detection (PHINDER)

United Therapeutics · NCT05776225

This study is trying to find the best ways to check for pulmonary hypertension in people who have interstitial lung disease to catch it earlier and improve their care.

Quick facts

Study typeObservational
Enrollment200 (estimated)
Ages18 Years and up
SexAll
SponsorUnited Therapeutics (industry)
Locations42 sites (Phoenix, Arizona and 41 other locations)
Trial IDNCT05776225 on ClinicalTrials.gov

What this trial studies

This observational study aims to evaluate screening strategies for pulmonary hypertension (PH) in patients diagnosed with interstitial lung disease (ILD). Participants will undergo a variety of clinical assessments, including pulmonary function tests, echocardiography, and right heart catheterization, to identify clinical parameters that may indicate the presence of PH. The goal is to develop a screening algorithm that can help detect PH earlier in patients with ILD. The study consists of two visits: a Screening Visit and a Study Visit 1.

Who should consider this trial

Good fit: Ideal candidates include patients diagnosed with interstitial lung disease who exhibit at least two signs or symptoms suggestive of pulmonary hypertension.

Not a fit: Patients who have previously undergone right heart catheterization with a mean pulmonary arterial pressure greater than 20 mmHg or are currently on FDA-approved pulmonary arterial hypertension medication may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could lead to earlier detection and management of pulmonary hypertension in patients with interstitial lung disease.

How similar studies have performed: While this approach is novel in its specific focus on screening for PH in ILD patients, similar studies have shown success in identifying pulmonary hypertension in other patient populations.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria

1. Patient gives voluntary written informed consent to participate in the study.
2. Patients with a diagnosis of ILD based on computed tomography imaging, including:

   1. Idiopathic interstitial pneumonia, including idiopathic pulmonary fibrosis
   2. Connective tissue disease-associated ILD with forced vital capacity (FVC) \<70%
   3. Hypersensitivity pneumonitis
   4. Scleroderma-related ILD
   5. Autoimmune ILD
   6. Nonspecific interstitial pneumonia
   7. Occupational lung disease
   8. Combined pulmonary fibrosis and emphysema
3. Patients must have at least 2 signs or symptoms suggestive of PH, as specified by the study protocol.

Exclusion Criteria

1. Prior RHC with mPAP \>20 mmHg.
2. Currently on a Food and Drug Administration (FDA)-approved pulmonary arterial hypertension medication.
3. Diagnosed with chronic obstructive pulmonary disease.
4. Uncontrolled or untreated sleep apnea.
5. Pulmonary embolism within the past 3 months.
6. History of ischemic heart disease or left-sided myocardial dysfunction within 12 months of Screening, defined as left ventricular ejection fraction \<40% or pulmonary capillary wedge pressure \>15 mmHg.
7. Any other clinical features that, in the opinion of the Investigator, might adversely affect interpretation of study data or study safety, or make the patient unsuitable for RHC.

Where this trial is running

Phoenix, Arizona and 41 other locations

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.

View on ClinicalTrials.gov →

Conditions: Interstitial Lung Disease, Pulmonary Hypertension, ILD, PH, PH-ILD

Last reviewed 2026-05-15 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.